<DOC>
	<DOCNO>NCT00069277</DOCNO>
	<brief_summary>The malignancy ( advanced solid tumor ) choose evaluation E7389 E7389 demonstrate significant pre-clinical anti-tumor activity , vitro vivo . The ultimate goal demonstrate clinical activity E7389 treatment , potentially , tumor type .</brief_summary>
	<brief_title>Study E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patients must histologically cytologically confirm measurable advanced solid tumor progress follow standard therapy standard therapy exists ( include surgery radiation therapy ) Patients may receive prior chemotherapy ( limit two prior chemotherapy regimen ) Patients must age &gt; = 18 year Patients must Karnofsky Performance Status &gt; 70 % Patients must life expectancy &gt; 3 month Patients must adequate renal function evidence serum creatinine &lt; 1.5 mg/dL creatinine clearance &gt; 60 mL/minute Patients must adequate bone marrow function evidence absolute neutrophil count &gt; 1,500/µL platelet &gt; 100,000/µL Patients must adequate liver function evidence bilirubin &lt; 1.5 mg/dL alanine transaminase ( ALAT ) aspartate transaminase ( ASAT ) &lt; 2 time upper limit normal Patients must willing able comply study protocol duration study Patients must give write informed consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice . Patients receive chemotherapy within three week ( six week nitrosoureas receive ) E7389 treatment start Patients recover chemotherapy relate therapy relate toxicity study entry Patients require therapeutic dos anticoagulant therapy ( eg , Coumadin , heparin , low molecular weight heparin ) . Low dose anticoagulant use patency ( e.g. , line , catheter , port ) permit . Women pregnant breastfeeding . Women childbearing potential either positive pregnancy test Screening pregnancy test . Women childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception opinion Investigator ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) Fertile men willing use contraception fertile men female partner willing use contraception Patients successfully complete local therapy previously treat central nervous system ( CNS ) metastases discontinued corticosteroid least four week start treatment E7389 . Patients asymptomatic brain metastasis evidence midline shift CT scan MRI may enrol without initiation local therapy CNS metastasis . In case , repeat scan must perform within four week original scan ensure disease progression occur . Patients test positive HIV Patients severe uncontrolled intercurrent illness/infection ( exclude malignancy ) Patients cardiovascular impairment Patients organ allografts Patients receive investigational drug , include immunotherapy , gene therapy , hormone therapy , biologic therapy ; antineoplastic therapy ; radiation therapy ( require palliation ) within three week E7389 treatment start Patients major surgery within four week E7389 treatment start without full recovery Patients hypersensitivity Halichondrin B and/or Halichondrin Blike compound Patients significant disease , Investigator 's opinion , would exclude patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Cancer , tumor</keyword>
</DOC>